We constructed a metabolic disorder model using HL‐1 mouse atrial cardiomyocytes stimulated with a long chain saturated fatty acid, PA, to investigate the correlation between FGF19 and the cardiometabolic phenotype of patients with AF.21, 22. This evidence concerns the gene FGF19 and metabolic disease.